Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer - Wikidata - awgldk - TriplyDB

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer

http://www.wikidata.org/entity/Q35631971

about

Persistent androgen receptor addiction in castration-resistant prostate cancer Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer Discovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments Deciphering the divergent roles of progestogens in breast cancer.Comparing the rules of engagement of androgen and glucocorticoid receptors Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer Targeting the glucocorticoid receptor in breast and prostate cancers.SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells.Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.SGK1 affects RAN/RANBP1/RANGAP1 via SP1 to play a critical role in pre-miRNA nuclear export: a new route of epigenomic regulation.Corticosterone activity during early weaning reprograms molecular markers in rat gastric secretory cells.Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci.Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer.Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients.Role of steroid receptor and coregulator mutations in hormone-dependent cancers.Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer.GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome.Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.

P2860

Q26777163-B86019FB-ABC3-4E4B-8F95-A508EEDD02E0 Q26777310-A0799C5D-D474-489A-A0C5-302CE3F2EF95 Q26782111-D7A7198A-0C2B-43C0-AE7F-D3545A305117 Q28078896-A8C2DCFE-547D-4AB7-836F-1AAF0C3E2FF9 Q30240711-2B003725-EB60-461A-901E-AA19F788D1EF Q33658855-63D38635-8C58-4302-80ED-E1EF6131F647 Q33672205-AB8310AF-268C-4150-88F6-C102ACD16A85 Q34461177-D92A0603-69AF-49D8-9EE0-698DD8AFAF3D Q34611922-DC8FE19A-438B-4FE5-87FE-185EA3F09610 Q36016635-C7263C7F-152B-4541-8C34-9311F39C3946 Q36398998-B6CD2EDC-FCFD-4AE9-8ED0-CCCEBEA3F463 Q36470627-F4112729-5E23-4670-8535-A3B3FD0887AD Q36545796-DC3CF657-7470-4901-AA53-E26FC27D4C80 Q36679783-FF8FF788-8622-4E8A-AD71-A7303C11F4A6 Q36729300-8650BBD8-F43B-49D9-9FD1-6A7CDE6285A7 Q37085905-727CBB20-1368-4929-8BC1-7CC17EC681EA Q37295639-C78152CD-AE98-4A29-8BF2-A6319E7EB8DF Q37638982-61E2F8A2-8BA3-4E73-B1EF-7302177F79B5 Q37709535-DCFE7FFB-3C27-471F-AB4B-B93A3D88D220 Q37727820-C0A27A61-35F2-47F1-9390-E0B698DF6191 Q37731369-03F3EFC6-F91C-428A-8538-000F85A642F4 Q37737611-3A423D5A-B9E3-41A8-A3E7-00081A75346B Q38375588-9D0A09FC-0B6A-42A2-83A2-04F1C7D18F4F Q38503798-2C345FC9-64E4-4F9C-AA00-7EB7281159F8 Q38543678-D72C3DFC-B0D4-4497-9052-2369BB1A5CDC Q38661520-6EF350DC-F9FF-4808-B976-306946F4C818 Q38703309-3F89BC86-ACD3-4C33-ADA3-E8004C833EC7 Q38736287-45C35431-DB12-4481-B340-807D98DCFF92 Q38827723-E430AC07-D247-41D9-97C2-C5F1503DA263 Q38865487-023871E0-B177-4562-881B-590D7015973D Q38902106-596767D8-760F-4109-82A7-C954B9289C15 Q38961091-1C01A804-FF32-49D8-A620-B7DDB45B7270 Q38964546-F9DD97FC-ACB6-47FF-A405-0215C425F6BD Q39016544-3A30CB3C-1230-44A0-B4CF-2A29A798D827 Q39041932-254916B3-3A5E-4317-A7F3-2E48BB2B3677 Q39215035-46B44F0F-2999-49E6-95E9-FC676F1EF53B Q39349569-0A4981B5-2379-451B-9E47-60891DAEA8D0 Q39798790-D7159863-95B5-4378-B1F9-370389A5F9D7 Q41349840-4D25D8E5-8DAD-479E-939E-9B9CFEE1C5D1 Q41824705-02C8B07B-AE45-4997-A102-A73531DC1B2D

P2860

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer

http://www.wikidata.org/entity/Q35631971

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Glucocorticoid receptor activi ...... ted therapy in prostate cancer

@ast

Glucocorticoid receptor activi ...... ted therapy in prostate cancer

@en

type

label

Glucocorticoid receptor activi ...... ted therapy in prostate cancer

@ast

Glucocorticoid receptor activi ...... ted therapy in prostate cancer

@en

prefLabel

Glucocorticoid receptor activi ...... ted therapy in prostate cancer

@ast

Glucocorticoid receptor activi ...... ted therapy in prostate cancer

@en

P1433

Q35631971-74A36A31-283B-43C9-8EDE-4B787E7BB23C

P1476

Q35631971-28AC326A-4527-4C22-ABE2-15F50645742A

P2093

Q35631971-1BABBE6F-F246-4707-BE5F-4B99961F76C9

Q35631971-3E30A595-3A6B-45FF-A944-21EF4752B61D

Q35631971-8DDE8516-20D0-4A60-A536-E96587BC2E01

Q35631971-AE26818B-35A6-49CF-AA82-10F7284C68C7

Q35631971-C84730C3-0F33-4AEF-B6C8-FFC5AC798313

Q35631971-CC22048A-507E-4536-9935-46314069BDD4

Q35631971-FC2D79AB-0746-4CEA-928E-417D649F09DF

P2860

Q35631971-009E7517-8FA5-4EDF-90CC-64B74730C616

Q35631971-056B09C1-64A8-48AA-8499-3AD6B3D98441

Q35631971-0A1CCF41-77D9-4B46-B0A0-7054AE1EB955

Q35631971-110A20B2-6406-43E4-BCCE-9EC61A477338

Q35631971-23D9FD77-1ACD-44DC-9A15-6DA49821AB5F

Q35631971-27EB1538-E816-40DF-BF5C-389A5D4824A8

Q35631971-28FB6382-A9FF-4ADD-BE26-3C9022373D73

Q35631971-3B63ADEC-A30C-4237-AC57-6C2D72F04643

Q35631971-3EF8DD96-084D-402B-97FD-B3A1B08FF609

Q35631971-441276A9-6730-4A5C-9AA4-0631E63B3385

P2888

Q35631971-486C5339-8263-4D75-8D07-CCC9156A1472

P304

Q35631971-F5C5FF22-5667-401A-9D80-D68A52A3F295

P31

Q35631971-B8E18C04-0EF4-46E2-871E-4FAC1AA31534

P356

Q35631971-41418254-DDFB-4A26-8191-296006A9A02D

P433

Q35631971-E30909BB-D7DA-407B-84A3-F7696E78415C

P478

Q35631971-BC26F75C-F073-48F0-BFDC-CF9BA571C66A

P50

Q35631971-BE001F9D-7DA7-45A9-9BF0-B38F4F8A729C

P577

Q35631971-423EC749-B8A3-4901-A895-E4AAEEAFAC43

P5875

Q35631971-4076DDE2-89BE-4314-BD77-88B85726C176

P698

Q35631971-C570158F-BB3B-45B1-B524-815FDB1903BB

P932

Q35631971-2B4C5D13-2836-4949-9365-25C49D0A5B26

P356

S12672-014-0173-2

P1433

Hormones and Cancer

P1476

Glucocorticoid receptor activi ...... ted therapy in prostate cancer

@en

P2093

Jacob Kach

http://www.w3.org/2001/XMLSchema#string

Kristen Otto

http://www.w3.org/2001/XMLSchema#string

Masis Isikbay

http://www.w3.org/2001/XMLSchema#string

Russell Z Szmulewitz

http://www.w3.org/2001/XMLSchema#string

Steven Kregel

http://www.w3.org/2001/XMLSchema#string

Suzanne D Conzen

http://www.w3.org/2001/XMLSchema#string

Yi Cai

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer

Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors

Overcoming mutation-based resistance to antiandrogens with rational drug design

Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor

Increased survival with enzalutamide in prostate cancer after chemotherapy

The current state of preclinical prostate cancer animal models.

Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.

P2888

s12672-014-0173-2

P304

72-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12672-014-0173-2

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Donald J Vander Griend

P577

2014-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260683827

http://www.w3.org/2001/XMLSchema#string

P698

24615402

http://www.w3.org/2001/XMLSchema#string

P932

4440041

http://www.w3.org/2001/XMLSchema#string